Absorbable Stent Articles & Analysis
5 news found
” Due to their temporary nature, bioresorbable stents are commonly referred to as scaffolds. MOTIV ’s polymer properties also enable complete x-ray visibility of the scaffold when placed in the artery, an attribute unique to REVA among bioresorbable scaffolds. REVA believes that this distinct feature will offer a procedural advantage, as x-ray visibility helps confirm ...
A £1.1 million project to develop biodegradable stents for patients with severe vascular disease, which affects around one million people in the UK, has started thanks to Innovate UK funding. The unique project, a collaboration between the UK-based medical device company Arterius and the Translational Biomedical Research Centre (TBRC) at the University of Bristol, will develop a new type of ...
Following the successful completion of the R&D project in 30th September 2016 (supported by a Smart award from the Innovate UK (TSB), Arterius has recently been awarded further funding from the Biomedical Catalyst-Early Stage programme to conduct the In-vitro and In-vivo GLP Evaluation of the Novel Bioresorbable Coronary Scaffolds; ArterioSorb. ArterioSorb is an innovative medical implant ...
Arterius Limited, a Leeds-based, UK company developing innovative medical devices with a focus on next generation bioresorbable coronary and peripheral stents, has announced that it has appointed Steve Parker as Chief Executive Officer. In the role Steve will lead the next phase of developing and scaling the business as it moves closer to commercialization of it’s suite of innovative and ...
Arterius Limited, a Leeds-based, UK company developing innovative medical devices with a focus on next generation bioresorbable coronary and peripheral stents, has announced that it has appointed Christopher (Chris) Meredith as Chairman of the Board of Directors. In this role, Chris will manage the Board and help Arterius develop and drive the commercial strategy for the successful launch of a ...